CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

Persistent luminescence nanoparticles excitable in situ for in vivo optical imaging, multimodal optical/MRI imaging and theranostics

Référence

86609-04

Statut des brevets

French patent application FR1250846 filed on January 30, 2012 and entitled “Nanoparticules a luminescence persistante pour l’imagerie optique en temps réel, l’imagerie multimodale optique-IRM in vivo et la theranostique”.

Inventeurs

Daniel SCHERMAN
Thomas MALDINEY
Cyrille RICHARD
Didier GOURIER
Bruno VIANA
Aurélie BESSIERE

Statut commercial

Exclusive or non-exclusive licenses, Collaborative agreement

Laboratoire

Description

CONTEXT

Biological optical imaging greatly relies upon the use of sensitive and stable optical labels. So far, organic dyes, quantum dots, and metal nanoparticles are the most commonly used optical labels but still have some limitations. When used in vivo, fluorescent probes present numerous drawbacks such as autofluorescence coming from tissue organic components during probe illumination. In addition, deep tissue imaging is difficult because of critical absorption from major components present in living organism (water, melanin, haemoglobin, lipids). 

TECHNICAL DESCRIPTION

The invention relates to using persistent luminescence nanoparticles, functionalized if necessary, in the form of a diagnosis agent for an in vivo optical imaging. Said nanoparticles are preferably consist of a compound selected from a group comprising gallates, aluminates, indates, gallogermanates, galloaluminates, galloindates, gallium oxides, indium oxides, magnesium oxides, wherein said compound is doped with one rare earth ion or with one transition metal ion (chrome, europium, cerium, nickel, iron, copper, cobalt).
These inorganic persistent luminescence particles can be excited in vivo after injection (wavelength between 550-1000 nm) before emitting in near-infrared range.

The nanoparticles may be encapsulated in mesoporous silica permitting delivery of molecules of biological interest.

The invention also relates to using persistent luminescence nanoparticles for an in vivo multimodal optical/MRI imaging through adding paramagnetic elements Cr3+, Mn2+, Gd3+, Fe3+ or Ni3+. 

BENEFITS

This method has important advantages over current imaging methods:

  • Long lasting luminescence
  • Persistent luminescence nanoparticles excited in situ after injection
  • Observation in real time without autofluorescence of endogenous fluorophores
  • Possible real-time monitoring of biodistribution of cells
  • Functionalization with molecules of biological interest
  • Size of the nanoparticles compatible with biological applications (between 50 and 100 nm)
  • Bimodal optical/MRI imaging

INDUSTRIAL APPLICATIONS

This innovation could be used for:

  • In vivo imaging
  • In vitro diagnosis with pre-functionalized nanoparticles

Theranostics (by use of mesoporous persistent luminescence “core-shell”)

Articles

Maldiney et al., 2012, Int J Pharm. ”Synthesis and functionalization of persistent luminescence nanoparticles (…)”,
Maldiney et al., 2012, Bioconjug Chem.

For further information, please contact us (Ref 86609-04)

Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents